LEL Lilly(Eli)

 
TIDMLEL 
 
Date: October 11, 2011 
 
For Release: Immediately 
 
Refer to: (317) 612-4974 Janice Chavers, chaversjm@lilly.com 
 
(317) 985-6303 Edward Sagebiel, egs@lilly.com 
 
                 Lilly Announces Changes in Senior Management 
 
              Carmine,Deane retiring;Ricks, Crowe, Azar promoted 
 
INDIANAPOLIS - Eli Lilly and Company (NYSE: LLY) today announced key 
appointments due to the December 31 retirements of longtime senior leaders, 
Bryce D. Carmine and Frank Deane, Ph.D. 
 
Carmine, whose Lilly career spans 36 years, has led Lilly Bio-Medicines since 
its creation in 2009. And Deane, whose career at Lilly spans 33 years, has led 
global manufacturing operations since 2007. Previously, both held numerous 
high-level leadership posts around the globe. 
 
John C. Lechleiter, Ph.D., chairman, president, and chief executive officer, 
described Carmine and Deane as "pillars of the company who have had a lasting, 
worldwide impact on our people and our business. We're grateful for their 
dedicated service." 
 
Effective January 1: 
 
  * Dave Ricks, president of Lilly USA, is being promoted to succeed Carmine as 
    senior vice president and president of Lilly Bio-Medicines. Ricks formerly 
    was general manager of Lilly affiliates in China and Canada. Ricks' 
    responsibilities will include the U.S., Japan, and Europe. Bio-Medicines 
    encompasses the therapeutic areas of neuroscience, cardiovascular, 
    autoimmunity, musculoskeletal, and urology. 
 
  * Maria Crowe, senior vice president for global drug product manufacturing, 
    is being promoted to succeed Deane as president of manufacturing 
    operations. She formerly was general manager of manufacturing sites in 
    Ireland and Puerto Rico. As head of manufacturing operations, she will lead 
    a network of 22 sites in 13 countries and also will have responsibility for 
    Lilly's global contract-manufacturing organization. 
 
  * Alex Azar, following Ricks' promotion, is being promoted to president of 
    Lilly USA, the company's largest affiliate. Azar has been vice president of 
    U.S. managed healthcare services and Puerto Rico since 2009. Azar joined 
    the company in 2007 as senior vice president of Lilly's global corporate 
    affairs and communications division. Prior to joining Lilly, he served as 
    the Deputy Secretary of the U.S. Department of Health and Human Services. 
 
"We'll certainly miss Bryce and Frank and the extraordinary leadership they 
provided," Lechleiter said. "At the same time, we're very fortunate to have 
talented leaders who are well-prepared and ready to step into these critical 
roles." 
 
Additional details about the individuals involved in today's announcements: 
 
David Ricks, a 15-year Lilly veteran, has led three of Lilly's most important 
affiliates: the U.S., China, and Canada. As president of Lilly USA since 2009, 
Ricks spearheaded a new operating model focused on increasing customer 
satisfaction and sustaining revenue growth while preparing for patent losses 
and significant changes to the health care system in the United States. 
 
Ricks joined Lilly in 1996 as a business development associate and held several 
management roles in U.S. marketing and sales before moving into key 
international roles for seven years - most recently as president and general 
manager of Lilly's affiliate in China, one of the world's fastest-growing 
pharmaceutical markets. He previously served as general manager of Lilly Canada 
after roles there as director of pharmaceutical marketing and national sales 
director. 
 
Ricks earned a bachelor's degree in business from Purdue University and an MBA 
from Indiana University. Prior to joining Lilly, Ricks held positions with 
Hewlett-Packard Corp. and IBM. 
 
Maria Crowe has served as senior vice president for global drug product 
manufacturing since August 2009. In this role, she has overseen all of Lilly's 
drug product manufacturing, packaging, and distribution operations. This 
includes sites that manufacture tablets and capsules as well as those that 
manufacture sterile injectable products. 
 
In her 29-year Lilly career, Crowe has held numerous roles in drug product and 
active pharmaceutical ingredient (API) manufacturing, as well as in sourcing 
and procurement. Prior to her current role, Crowe was vice president for drug 
product manufacturing in the Americas (the United States and Latin America). 
Crowe also served as general manager at Lilly's Kinsale, Ireland, plant; 
general manager of Lilly del Caribe in Puerto Rico; and plant manager of 
Lilly's Elanco manufacturing plant at the former Tippecanoe manufacturing site. 
 
Crowe holds a bachelor's degree in industrial management from Purdue 
University. 
 
Alex Azar joined Lilly in 2007 as senior vice president of corporate affairs. 
In 2009, he became vice president of U.S. managed health care services and 
Puerto Rico. In that role, he has led the company's managed care, public payer, 
hospital, wholesaler, and retailer operations in the United States as well as 
Lilly's sales and marketing operations in Puerto Rico. 
 
Before joining the company, Azar served as the U.S. Deputy Secretary of Health 
and Human Services (HHS), the largest civilian department in the federal 
government. Before entering government, he was a partner at the Washington, 
D.C., law firm of Wiley, Rein & Fielding. Azar earned a bachelor's degree in 
economics and government from Dartmouth College and is a graduate of Yale Law 
School. 
 
Bryce D. Carmine has led Lilly Bio-Medicines since September 2009, when the 
company reorganized its pharmaceutical business into the operating model that 
exists today. Carmine's prior roles have included executive vice president of 
global marketing and sales, president of global product development, president 
of metabolic disorders and specialty products, and managing director in Japan. 
He joined Lilly in 1975 as a sales representative in New Zealand. 
 
Frank Deane, Ph.D., became president of global manufacturing operations in June 
2007. He had been vice president of quality since December 2001. His previous 
roles have included management in Ireland and Puerto Rico. He returned to the 
United States in 1993 as general manager of U.S. pharmaceutical manufacturing 
and assumed responsibility for Lilly's worldwide API manufacturing operations 
in 1997. He joined Lilly in 1979 as a technical coordinator in manufacturing in 
Indianapolis. 
 
About Lilly 
 
Lilly, a leading innovation-driven corporation, is developing a growing 
portfolio of pharmaceutical products by applying the latest research from its 
own worldwide laboratories and from collaborations with eminent scientific 
organizations. Headquartered in Indianapolis, Ind., Lilly provides answers - 
through medicines and information - for some of the world's most urgent medical 
needs. Additional information about Lilly is available at www.lilly.com. C-LLY 
 
                                     # # # 
 
 
 
Eli Lilly and Company 
 
Lilly Corporate Center 
 
Indianapolis, Indiana 46285 
 
U.S.A. 
 
www.lilly.com 
 
 
 
 
 
 
 
 
 
 
END 
 

Lilly(Eli) (LSE:LEL)
Historical Stock Chart
From Jan 2025 to Feb 2025

Lilly(Eli) (LSE:LEL)
Historical Stock Chart
From Feb 2024 to Feb 2025